Hidden Hypercalcemia and Mortality Risk in Incident Hemodialysis Patients

Permalink
https://escholarship.org/uc/item/7vx150fz

Journal
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 101(6)

ISSN
0021-972X

Authors
Obi, Y
Mehrotra, R
Rivara, MB
et al.

Publication Date
2016-06-01

DOI
10.1210/jc.2016-1369

License
CC BY 4.0

Peer reviewed
Hidden Hypercalcemia and Mortality Risk in Incident Hemodialysis Patients

Yoshitsugu Obi, Rajnish Mehrotra, Matthew B. Rivara, Elani Streja, Connie M. Rhee, Wei Ling Lau, Csaba P. Kovesdy, and Kamyar Kalantar-Zadeh

Division of Nephrology and Hypertension (Y.O., E.S., C.M.R., W.L.L., K.K.-Z.), Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine, School of Medicine, Orange, California 92868; Division of Nephrology (R.M., M.B.R.), Kidney Research Institute and Harborview Medical Center, University of Washington, Seattle, Washington 98104; Division of Nephrology (C.P.K.), University of Tennessee Health Science Center, Memphis, Tennessee 38103; Nephrology Section (C.P.K.), Memphis VA Medical Center, Memphis, Tennessee 38104; Fielding School of Public Health at University of California at Los Angeles (K.K.-Z.), Los Angeles, California 90024; and Los Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (K.K.-Z.), Torrance, California 90502

Context: Neither uncorrected- nor albumin-corrected total calcium reliably predict ionized calcium in patients with end-stage renal disease. However, little is known about the consequences of inaccurate assessment of calcium concentration using total calcium.

Objective: We hypothesized that hidden hypercalcemia (ie, elevated ionized calcium with normal total calcium) and apparent hypercalcemia (ie, elevated ionized calcium with elevated total calcium) are both associated with increased mortality risk.

Design, Setting, and Patients: We identified 874 incident hemodialysis patients with measured serum ionized calcium, total calcium, albumin, phosphorus, and bicarbonate from October 2007 to December 2011, using data from a large dialysis organization in the United States.

Exposures: Serum concentrations of ionized calcium and total calcium were measured.

Main Outcome Measure: The primary outcome was all-cause mortality.

Results: There was only fair interindex agreement with calcium status between ionized calcium and uncorrected or corrected total calcium (κ = 0.32 and 0.27, respectively). Among patients with high ionized calcium (>1.32 mmol/liter), 88% and 70% patients were incorrectly categorized as being normocalcemic using uncorrected and corrected total calcium, respectively, and were thus considered to have “hidden hypercalcemia.” Compared to patients with low-normal ionized calcium (1.16–1.24 mmol/liter), patients with high ionized calcium had a significantly higher mortality risk (adjusted hazard ratio, 1.77; 95% confidence interval, 1.13–2.75). Furthermore, compared to patients with normocalcemia (ionized calcium 1.16–1.32 mmol/liter), those with hidden hypercalcemia by uncorrected and corrected total calcium also had a higher risk for death (adjusted hazard ratio 1.75 [95% confidence interval 1.11–2.75] and 1.80 [95% confidence interval, 1.11–2.90], respectively).

Conclusion: The majority of end-stage renal disease patients with elevated ionized calcium are incorrectly categorized as normocalcemic using conventional total calcium measurements; these patients have a higher death risk. Future research is needed to establish whether reducing ionized calcium concentrations in these patients improves clinical outcomes. (J Clin Endocrinol Metab 101: 2440–2449, 2016)
Hypercalcemia is an established risk factor for death among patients with end-stage renal disease (ESRD) (1–8). In the predialysis period, serum calcium concentrations decrease as kidney function declines because of decreased intestinal calcium absorption and diminished renal tubular reabsorption, which is attributed to blunted activation of vitamin D in the kidney resulting from elevated fibroblast growth factor-23 and reduced functioning renal mass (9–11). Serum calcium concentrations then rise following the initiation of hemodialysis (4), likely from decreased renal calcium excretion, active vitamin D treatment, calcium-based phosphate binders, and/or hyperparathyroidism. Elevated extracellular calcium levels, along with hyperphosphatemia, raise the risk of vascular calcification, which leads to the development of cardiovascular disease in this population (12–14). Given these observations, current clinical practice guidelines for patients with ESRD suggest maintaining total serum calcium concentrations within the normal range (15).

Approximately 45% of total serum calcium is in the form of physiologically active ionized calcium. However, in clinical practice, total calcium is typically measured in lieu of ionized calcium given its lower cost and less time and effort needed to process and test samples. Several correction equations using both total calcium and serum albumin have been developed to predict ionized calcium concentrations given the experimental findings that approximately 40% of total calcium is bound to albumin with a ratio of 0.8 mg of calcium per 1 g of albumin in normal subjects (16). However, the proportion of albumin-bound serum calcium varies according to acid-base balance. Additionally, serum calcium also binds to multiple organic and inorganic anions including sulfate, bicarbonate, and phosphate. Previous studies have demonstrated that neither uncorrected nor corrected total calcium adequately predict ionized calcium concentrations in patients with advanced kidney disease (17–20), in part because of frequent accompaniment of metabolic acidosis, hyperphosphatemia, and high plasma sulfate concentrations. As a result, clinical practice guidelines also support ionized calcium measurement as the preferred method to evaluate calcium status in patients with advanced kidney diseases (15).

Although the prevalence of high albumin-corrected total calcium (>10.2 mg/dl) has been decreased over time from 20% in the early 2000s to 4–5% in the 2010s (21, 22), there are currently few data regarding the implications of discrepant total and ionized calcium concentrations upon clinical outcomes in patients with ESRD. Because ionized calcium is infrequently measured in clinical practice, we examined a 5-year cohort of incident hemodialysis patients treated in facilities operated by a large dialysis organization in the United States, hypothesizing that hidden hypercalcemia (ie, elevated ionized calcium with normal total calcium) and apparent hypercalcemia (ie, elevated ionized calcium with elevated total calcium) are both associated with increased mortality risk.

Subjects and Methods

This study was approved by the Institutional Review Boards of the Los Angeles Biomedical Research Institute at Harbor-University of California Los Angeles, University of California Irvine Medical Center, and the University of Washington as exempt from informed consent.

Patients

We extracted, refined, and examined electronic data from all incident dialysis patients who were age at least 18 years and received conventional hemodialysis treatment in facilities operated by a large dialysis organization in the United States from October 1, 2007, to December 31, 2011 (23). We excluded patients who ever been treated with peritoneal dialysis, home hemodialysis, or nocturnal in-center hemodialysis from this study. Of 128 675 patients who were treated with conventional hemodialysis only during follow-up, we identified 1246 patients with 10 458 ionized calcium measurements. We excluded 48 measurements performed in between hemodialysis sessions (ie, during the interdialytic period), 84 measurements done in patients receiving cinacalcet, 87 measurements with extreme values (<0.5 or >99.5th percentile), and 174 measurements in patients dialyzed against <2.0 mEq/liter or >3.0 mEq/liter calcium. Because the fraction of ionized calcium against total calcium is influenced by serum concentrations of albumin, phosphorus, and bicarbonate (17–20, 33, 34), we also excluded 668 measurements with missing simultaneous evaluation of these variables. We then restricted measurements to those obtained during the first 91 days of dialysis treatment. The final analytic cohort was comprised of 874 incident hemodialysis patients (Figure 1).

Demographic, clinical, and laboratory measures

Information on race/ethnicity, primary insurance, access type, and International Classification of Diseases-9 codes were obtained from the electronic database of the dialysis provider. International Classification of Diseases-9 codes were used to determine the following comorbidities: diabetes mellitus, hypertension, dyslipidemia, atherosclerotic heart disease, congestive heart failure, cerebrovascular disease, and other cardiovascular disease. Blood samples were drawn using uniform techniques in all dialysis clinics and were transported to the central laboratory in Deland, Florida, typically within 24 hours. All laboratory values were measured by automated and standardized methods. Specifically, serum ionized calcium and albumin was measured by using ion-selective electrode and bromocresol green. Most blood samples were collected predialysis with the exception of the postdialysis urea that was obtained to calculate urea kinetics. Single-pool Kt/V delivered by dialysis was calculated using urea kinetic modeling equations (24, 25). Albumin-corrected total calcium was calculated as follows (15):
Corrected total calcium = measured serum total calcium
+ \(0.8 \times (4.0 - \text{serum albumin})\) if \(\text{serum albumin} < 4.0\)

Because serum concentrations of albumin, total calcium, phosphorus, and bicarbonate, and medication use (ie, oral/IV active vitamin D and calcium-based phosphorus binders) are closely related to calcium status, those data were extracted from the same days of ionized calcium measurements, whereas data for body mass index (BMI) and other laboratory variables including single-pool Kt/V, hemoglobin, creatinine, and ferritin, were extracted during the first 91 days of dialysis. Those repeated measures were then averaged and used in all analyses to minimize measurement variability.

**Statistical analysis**

Patient characteristics are expressed as mean ± SD, medians (interquartile range), or percentages, as appropriate. Differences between included and excluded patients were compared by standarded differences because of the large sample size of this study (26, 27).

Total and ionized calcium was categorized as low (<8.6 mg/dL and <1.16 mmol/liter, respectively), low-normal (8.6 to 9.4 mg/dl and 1.6 to 1.24 mmol/liter, respectively), high-normal (>9.4 to 10.2 mg/dL and >1.24 to 1.32 mmol/liter, respectively), and high (>10.2 mg/dL and >1.32 mmol/liter, respectively). The \(z\)-statistic measure was used to evaluate the interindex agreement for categories of calcium status.

Cox proportional hazards models were used to analyze the association between calcium status and all-cause mortality. For comparison between calcium indices, uncorrected total calcium, and ionized calcium values were also normalized by conversion to a \(z\) score based on the normal range in the central laboratory (not a data-derived \(z\) score) as follows (17–20): the lower and upper limits of the normal ranges for ionized calcium (1.16 and 1.32 mmol/liter) and total calcium (8.6 and 10.2 mg/dl) were treated as the 95% confidence intervals (CIs) and used to calculate the mean and SD by the formula “\(z\) score = \(\frac{\text{measured value} - \text{mean}}{\text{SD}}\times 1.96\)” where the mean and SD were 1.24 and 0.08 mmol/liter and 9.4 and 0.8 mg/dl for ionized and total calcium, respectively. The association of each \(z\) score with mortality was then modeled using restricted cubic splines with knots placed at the fifth, 35th, 65th, and 95th percentiles of exposure. Median values of each calcium index were used as a reference.

For each model, three levels of adjustments were used as follows: 1) minimally adjusted models that included age, sex, race, and ethnicity (non-Hispanic white, non-Hispanic Black, and other race/ethnicity), central venous catheter use as vascular access, and diabetes; 2) case-mix adjusted models that included the above plus primary insurance (Medicare, Medicaid, and other), natural log-transformed BMI, and history of hypertension and cardiovascular disease; and 3) fully adjusted models that included all covariates in the case-mix model plus laboratory variables (ie, single-pool Kt/V; hemoglobin; serum concentrations of albumin, creatinine, phosphorus, and bicarbonate; and natural log-transformed intact PTH and ferritin) and medication use (active vitamin D [either oral or IV] and oral calcium salts [either calcium acetate or calcium carbonate]). Because of the limited number of outcomes, we used the minimally adjusted models as the primary analyses. When estimating the mortality risk of hidden hypercalcemia, we also used backwards Akaiake’s information criterion (AIC)-based Cox regression to the fully adjusted models, which included age, race and ethnicity, central venous catheter use, history of hypertension, hemoglobin, serum albumin, serum phosphorus, serum bicarbonate, the use of active vitamin D, and the use of oral calcium salts, to balance the tradeoff between precision and overfitting. Proportional hazards assumptions were tested using Schoenfeld residuals and log-log plots against survival.

The frequency of missing covariate data was low (1.0%, 0.1%, 0.6%, 0.6%, and 0.9% for single-pool Kt/V, hemoglobin, creatinine, and natural log-transformed intact PTH and ferritin, respectively), and multiple imputation method with five data sets was used in Cox regression analyses. Available data for oral medication use were limited to clopidogrel or medications related to lipid and bone mineral metabolism. Fourteen percent of patients had no available oral medication data, and they were considered nonusers of active vitamin D compounds or calcium salts. We conducted all analyses using STATA MP, version 13.1 (StataCorp).
ing the first 91 days of dialysis treatment (Table 1). The mean ± SD concentrations of ionized calcium, uncorrected total calcium, and albumin-corrected total calcium were 1.19 ± 0.10 mmol/liter, 8.6 ± 0.7 mg/dl, and 9.1 ± 0.6 mg/dl, respectively. Compared to excluded incident hemodialysis patients in whom ionized calcium, serum albumin, total calcium, phosphorus, and bicarbonate were not simultaneously measured during the first 91 days of dialysis treatment, included patients were less likely to be Hispanics or minorities; were more likely to be treated with lower dialysate calcium baths; and were more likely to have higher bicarbonate concentrations (standard deviation >20%, Supplemental Table 1). In the overall cohort, 77 patients (9%) had hypercalcemia defined by ionized calcium (>1.32 mmol/liter) (Table 1).

We categorized patients into a low, low-normal, high-normal, or high calcium group based on each index, and then compared the concordance of calcium status between ionized calcium and uncorrected/uncorrected total calcium (Table 2). Among 77 patients with high ionized calcium (>1.32 mmol/liter), 68 (88%) and 55 (71%) were incorrectly categorized as normocalcemic using uncorrected and corrected total calcium (>10.2 mg/dl), respectively. Likewise, among 284 patients with low ionized calcium (<1.16 mmol/liter), 55 (19%) and 164 (58%) were incorrectly categorized as normocalcemic using uncorrected and corrected total calcium (>10.2 mg/dl), respectively. Overall, the kappa statistics against ionized calcium status were 0.32 and 0.27 for uncorrected and corrected total calcium, respectively, indicating only a fair agreement with each index (28).

## Association of calcium indices with mortality

A total of 227 deaths were observed during a total follow-up period of 1174 patient-years, with an overall crude rate of death of 193 per 1000 patient-years. Figure 2 depicts the crude mortality and the adjusted hazard ratios (HRs) for all-cause death according to calcium status by uncorrected, corrected, and ionized calcium. The highest mortality was observed in patients with hypercalcemia regardless of calcium indices. In the minimally adjusted models (the primary analysis), the estimated HRs of hypercalcemia were high in uncorrected and corrected total calcium, but the number of events in these categories were limited (n = 4 and n = 9, respectively), and these associations were not statistically significant (Figure 2, B and C). Meanwhile, 28 of 77 patients with hypercalcemia (>1.32 mmol/liter) defined by ionized calcium died during the follow-up, and ionized hypercalcemia showed a significantly higher mortality risk with an HR of 1.76 (95% CI 1.14–2.71, P = .008).

### Table 1. Characteristics of 874 Incident HD Patients According to Ionized Calcium Concentrations

<table>
<thead>
<tr>
<th>Calcium Concentration</th>
<th>N (%)</th>
<th>Low &lt;1.16 mmol/liter (n = 284 (32%))</th>
<th>Low-Normal 1.16–1.24 mmol/liter (n = 335 (38%))</th>
<th>High-Normal &gt;1.24–1.32 mmol/liter (n = 178 (20%))</th>
<th>High &gt;1.32 mmol/liter (n = 77 (9%))</th>
<th>P for Trend</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>56</td>
<td>63 ± 15</td>
<td>63 ± 15</td>
<td>64 ± 15</td>
<td>67 ± 15</td>
<td>.01</td>
</tr>
<tr>
<td>Male</td>
<td>50</td>
<td>63%</td>
<td>62%</td>
<td>58%</td>
<td>51%</td>
<td>.003</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-Hispanic white</td>
<td>55%</td>
<td>44%</td>
<td>58%</td>
<td>60%</td>
<td>69%</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Non-Hispanic Black</td>
<td>35%</td>
<td>42%</td>
<td>33%</td>
<td>32%</td>
<td>26%</td>
<td>.003</td>
</tr>
<tr>
<td>Others</td>
<td>10%</td>
<td>14%</td>
<td>10%</td>
<td>8%</td>
<td>5%</td>
<td>.01</td>
</tr>
<tr>
<td>Insurance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicare</td>
<td>46%</td>
<td>44%</td>
<td>50%</td>
<td>44%</td>
<td>47%</td>
<td>.78</td>
</tr>
<tr>
<td>Medicaid</td>
<td>6%</td>
<td>6%</td>
<td>7%</td>
<td>4%</td>
<td>5%</td>
<td>.56</td>
</tr>
<tr>
<td>Others</td>
<td>48%</td>
<td>50%</td>
<td>44%</td>
<td>52%</td>
<td>48%</td>
<td>&gt;.99</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>56%</td>
<td>62%</td>
<td>54%</td>
<td>51%</td>
<td>55%</td>
<td>.04</td>
</tr>
<tr>
<td>Hypertension</td>
<td>46%</td>
<td>47%</td>
<td>44%</td>
<td>49%</td>
<td>42%</td>
<td>.78</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td></td>
<td>46%</td>
<td>50%</td>
<td>40%</td>
<td>39%</td>
<td>.15</td>
</tr>
<tr>
<td>CV catheter</td>
<td>77%</td>
<td>85%</td>
<td>77%</td>
<td>67%</td>
<td>70%</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Single-pool Kt/V</td>
<td>1.47</td>
<td>1.45 ± 0.34</td>
<td>1.47 ± 0.32</td>
<td>1.49 ± 0.31</td>
<td>1.48 ± 0.33</td>
<td>.22</td>
</tr>
<tr>
<td>BMI</td>
<td>26.8</td>
<td>26.4 (IQR, 23.0–31.7)</td>
<td>26.9 (IQR, 22.8–31.4)</td>
<td>27.1 (IQR, 23.4–32.2)</td>
<td>26.8 (IQR, 24.5–32.8)</td>
<td>.34</td>
</tr>
<tr>
<td>Dialysate calcium (mEq/liter)</td>
<td>2.25</td>
<td>2.3 (IQR, 2.0–2.5)</td>
<td>2.50 (IQR, 2.0–2.5)</td>
<td>2.25 (IQR, 2.0–2.5)</td>
<td>1.32 mmol/liter</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Active vitamin D (%)</td>
<td>32%</td>
<td>31%</td>
<td>35%</td>
<td>32%</td>
<td>25%</td>
<td>.42</td>
</tr>
<tr>
<td>Calcium salts (%)</td>
<td>12%</td>
<td>13%</td>
<td>10%</td>
<td>16%</td>
<td>10%</td>
<td>.92</td>
</tr>
<tr>
<td>Laboratories</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>10.9</td>
<td>10.6 ± 1.3</td>
<td>10.9 ± 1.4</td>
<td>11.0 ± 1.3</td>
<td>11.1 ± 1.4</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Albumin (g/dl)</td>
<td>3.4</td>
<td>3.3 ± 0.6</td>
<td>3.5 ± 0.5</td>
<td>3.5 ± 0.5</td>
<td>3.4 ± 0.6</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>5.7</td>
<td>6.2 ± 2.4</td>
<td>5.7 ± 2.4</td>
<td>5.2 ± 2.1</td>
<td>5.0 ± 1.9</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Uncorrected calcium (mg/dl)</td>
<td>8.6</td>
<td>8.0 (IQR, 7.7–8.5)</td>
<td>8.7 (IQR, 8.4–8.9)</td>
<td>9.0 (IQR, 8.9–9.4)</td>
<td>9.6 (IQR, 8.9–9.9)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Corrected calcium (mg/dl)</td>
<td>9.1</td>
<td>8.7 (IQR, 8.4–9.0)</td>
<td>9.1 (IQR, 8.9–9.3)</td>
<td>9.4 (IQR, 9.3–9.6)</td>
<td>10.0 (IQR, 9.7–10.3)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Phosphorus (mg/dl)</td>
<td>4.7</td>
<td>5.1 ± 1.5</td>
<td>4.7 ± 1.3</td>
<td>4.4 ± 1.0</td>
<td>4.3 ± 1.3</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Intact PTH (pg/ml)</td>
<td>315</td>
<td>413 (IQR, 263–627)</td>
<td>330 (IQR, 198–467)</td>
<td>249 (IQR, 142–351)</td>
<td>193 (IQR, 57–313)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Bicarbonate (mEq/liter)</td>
<td>24</td>
<td>24 ± 3</td>
<td>24 ± 3</td>
<td>24 ± 3</td>
<td>25 ± 3</td>
<td>.30</td>
</tr>
</tbody>
</table>

Values are expressed as mean (SD), median (IQR), or percentage, appropriately. SI conversion factors: to convert hemoglobin to g/liter, multiply by 10; albumin to g/liter, multiply by 10; creatinine to μmol/liter multiply by 88.4; calcium to mmol/liter, multiply by 0.25; phosphorus to mmol/liter, multiply by 0.323; PTH to ng/ml, multiply by 1.0; ferritin to pmol/liter, multiply by 2.247; bicarbonate to mmol/liter, multiply by 1.0.

Abbreviations: CV, central venous; IQR, interquartile range.
confidence interval [CI], 1.13–2.75); reference: low-normal ionized calcium [1.16–1.24 mmol/liter]) (Figure 2D). High-normal ionized calcium (>1.24–1.32 mmol/liter) was not associated with mortality (HR, 0.98 [95%CI, 0.67–1.42], \( P = .90 \)). Consistent findings were observed in the restricted cubic spline models by using Z scores of three calcium indices (Figure 3). High ionized calcium concentrations were significantly associated with death in the range beyond the upper normal limit of the central laboratory (>1.96 of Z score or >1.32 mmol/liter, the right vertical line; reference, 1.20 mmol/liter).

Hidden calcium abnormality and mortality

To examine the mortality risk associated with hidden calcium abnormality (ie, misclassification of calcium status using uncorrected and corrected calcium concentrations, in which ionized calcium served the “gold standard”), we conducted Cox regression analyses after categorizing patients into five groups, namely, “apparent hypocalcemia,” “hidden hypocalcemia,” “normocalcemia,” “hidden hypercalcemia,” and “apparent hypercalcemia” (Figure 4A). For uncorrected total calcium, the highest crude mortality was observed in patients with apparent hypercalcemia (HR, 1.75 [95% CI, 1.11–2.75], \( P = .02 \)) but not in those with hidden hypocalcemia (HR, 0.82 [95% CI, 0.45–1.50], \( P = .52 \)) (Figure 4C). In the sensitivity analysis using backwards AIC-based Cox regression, there was a trend toward a higher mortality risk of hidden hypercalcemia (HR 1.49 [95% CI, 0.94–2.35], \( P = .09 \)).

For corrected total calcium, the highest crude mortality rate was observed in patients with apparent hypercalcemia (Figure 4D). Patients with hidden hypercalcemia and hidden hypocalcemia showed the second and third highest crude mortality rates. In the minimally adjusted models (primary analysis), the mortality risk was significant both in patients with hidden hypercalcemia (HR, 1.80 [95% CI, 1.11–2.90], \( P = .02 \)) and those with hidden hypocalcemia (HR, 1.47 [95% CI, 1.05–2.06], \( P = .02 \)) (Figure 4E). Further adjustments for case-mix variables did not change these associations. The mortality risk of hidden hypocalcemia was attenuated and lost its statistical significance in the fully adjusted model, but the risk of hidden hypercalcemia remained significant. The mortality risk of hidden hypercalcemia was still significant in the sensitivity analysis using backwards AIC-based Cox regression (HR, 1.71 [95% CI, 1.05–2.78], \( P = .03 \)).

Discussion

To our knowledge, this is the largest study examining ionized calcium in patients with chronic kidney disease con-
ducted to date. In this 5-year cohort of incident hemodi-
alysis patients from a large dialysis organization in the
United States, high ionized calcium was associated
with higher mortality risk. However, we observed that there
was only fair interindex agreement with calcium status
between ionized and total calcium. Approximately 90%
and 70% of patients with ionized hypercalcemia were in-
correctly categorized as normocalcemic by uncorrected
and corrected total calcium concentrations, respectively,
and were considered to have “hidden hypercalcemia.”
When compared to normocalcemic patients, those with
hidden hypercalcemia using either uncorrected or cor-
corrected total calcium had significantly higher mortality
risk, as did those with apparent hypercalcemia.

Our study is the first to demonstrate that hemodialysis
patients with hidden hypercalcemia have higher mortality
risk. The low correlation between ionized vs uncorrected
or corrected total calcium has been shown in multiple pre-
vious studies (17–20). However, these findings have not
been acknowledged well in clinical practice guidelines be-
cause of the lack of data showing that misclassification of
calcium status is clinically relevant (15). A recent cohort
study of 160 hemodialysis patients did not find such an
association between ionized calcium and all-cause death
(29). However, there were only three patients with ionized
hypercalcemia (>1.32 mmol/liter), and the impact of the
discrepancy between ionized and total calcium on survival
was not examined. Our study found that the mortality risk
appeared to increase with ionized calcium concentrations
above the normal range irrespective of total calcium con-
centrations, suggesting that many hypercalcemic patients
may not come to clinical attention when calcium status is
evaluated by uncorrected or corrected total calcium con-
centrations alone.

Common criticisms of measuring ionized calcium in-
clude lower reproducibility, a more time-consuming pro-
cess, and higher costs than total calcium measurements
(30). Clinical application of this technique requires peri-
dodic maintenance, electrode replacement with associated
downtime, and redundancy of instrumentation and per-
sonnel (31). However, the previously used colorimetric
and biological assays have been replaced by much more
reliable ion-sensitive electrodes that are available both in
blood-gas instruments and automated chemistry analyz-
ers with equivalent analytical coefficients of variation to total calcium (32). Additionally, it is important when evaluating cost-effectiveness of a diagnostic test to weigh its measurement cost against potential medical costs induced by false-negative or false-positive diagnosis, especially when such misdiagnosis is associated with severe adverse events including cardiovascular disease and death.

An important limitation of this study is that the large size of the dialysis organization may have limited optimal processing needed for measurements of ionized calcium. To optimally measure ionized calcium, samples should be collected and managed anaerobically with complete filling of the blood sampling tube to avoid change in pH resulting from a loss of carbon dioxide (33, 34). A closed-tube automation system and analyzers would make serum ionized calcium measurement more reliable in clinical practice. Additionally, time to centrifugation and temperature during transfer also influences ionized calcium concentrations through pH change. However, those samples used in this study were collected for serum bicarbonate measurement as well. Several studies also demonstrated that serum ionized calcium can be measured without a significant error up to 24 hours from blood draw if samples are anaerobically collected and kept at below 4 C (35–37). Additionally, although ionized calcium concentrations in serum samples from dialysis patients show large positive and negative changes after 6-hour storage at 4 C, the mean difference across the patient population is low (37). This finding suggests that the mean ionized calcium concentrations from an adequate number of subjects can be used to estimate the population-level associations with clinical outcomes, albeit vulnerable to bias toward the null.

Several other limitations of our study should be noted when interpreting our results. First, available ionized calcium measures may not be representative of the entire source population. Potential selection bias may exist, such that physicians may be likely to measure ionized calcium in patients with low dialysate calcium concentration or unstable patients with suspected disease conditions that may induce calcium abnormality. Second, the risk of hidden hypocalcemia, but not hidden hypercalcemia, might have been overestimated if there remained residual con-

Figure 3. A panel of the associations of between all-cause mortality and each Z score of ionized (Zion), uncorrected (Zuncorr) total calcium, and corrected (Zcorr) total calcium with three-level adjustments. Vertical lines at –1.96 and 1.96 of Z score indicate the upper and lower limits of the normal range for each calcium index in the central laboratory, respectively.
Figure 4. Calcium status by the combination of ionized calcium and uncorrected/corrected calcium and their associations with mortality. (A) Definition of calcium status by the combination of ionized calcium and uncorrected/corrected calcium. (B) Crude mortality and (C) adjusted HR according to calcium status by the combination of ionized calcium and uncorrected total calcium. (D) Crude mortality and (E) adjusted HR according to calcium status by the combination of ionized calcium and corrected total calcium. The number of patients and all-cause death in each group is shown in the bottom of panels B and D. Points and lines represent point estimates and 95% CIs, respectively.
founding by central venous catheter use as vascular access. Indeed, heparin used for catheter lock lowers the fraction of ionized calcium by binding (33), and catheter use is a risk factor for mortality in hemodialysis patients (38). Third, the small sample size of patients with hidden or apparent calcium abnormality resulted in wide CIs for the estimated associations and might have inflated the likelihood of type II error in our analyses.

In conclusion, hidden hypercalcemia is common in incident hemodialysis patients and associated with higher mortality risk in this population. Prospective studies are needed to identify which subpopulations of chronic kidney disease patients who would most benefit from ionized calcium measurement vs routinely used uncorrected and corrected total calcium assays and to establish whether reducing ionized calcium concentrations in these patients improves clinical outcomes.

Acknowledgments

The authors thank DaVita Clinical Research for providing the clinical data for this research.

Address all correspondence and requests for reprints to: Kamyar Kalantar-Zadeh, MD, MPH, PhD, Harold Simmons Center for Kidney Disease Research and Epidemiology, University of California Irvine, 101 The City Drive South, City Tower, Suite 400, Orange, CA 92868. E-mail: kkjz@uci.edu.

The work in this manuscript has been performed with the support of the National Institute of Diabetes, Digestive and Kidney Disease (NIDDK) of the National Institutes of Health research grants R01-DK095668 (to R.M. and K.K.-Z.), K24-DK091419 (to K.K.-Z.), and R01-DK078106 (to K.K.-Z.); philanthropic grants from Harold Simmons, Louis Chang, Joseph Lee, and AVEO (to K.K.-Z.); NIDDK grants R01-DK096920 and U01-DK102163 (to C.P.K.); NIDDK grant K23-DK102903 (to C.M.R.); and the Shinya Foundation for International Exchange of Osaka University Graduate School of Medicine Grant (to Y.O.).


Preliminary results of this study have been partly presented as a poster at the National Kidney Foundation 2016 Spring Clinical Meetings, Boston, Massachusetts.

Disclosure Summary: K.K.-Z. has received honoraria from Abbott, Abbvie, Alexion, Amgen, Astra-Zeneca, AVEO, Chugai, DaiVita, Fresenius, Genentech, Haymarket Media, Hospira, Kabi, Keryx, Novartis, Pfizer, Relypsa, Resverlogix, Sandoz, Sanofi-Aventis, Shire, Vifor, UpToDate, and ZS Pharma.

C.P.K. has received honoraria from Abbott, Relypsa, Sanofi-Aventis, and ZS Pharma.

References

20. Ferrari P, Singer R, Agarwal A, et al. Serum phosphate is an impor-


